Breaking News, Collaborations & Alliances

Vasa Therapeutics’ Lead Drug Candidate Enters Clinical Trials

The first human subjects have been dosed at Quotient Sciences' Nottingham, UK clinic.

Author Image

By: Charlie Sternberg

Associate Editor

Vasa Therapeutics, a biotechnology company focused on developing innovative treatments for cardiovascular diseases, announced today that its lead drug candidate, VS-041, has entered clinical trials. The first human subjects have been dosed at Quotient Sciences’ Nottingham, UK clinic.   VS-041 is being developed as a potential treatment for heart failure with preserved ejection fraction (HFpEF), a condition affecting millions worldwide. HFpEF is characterized by a stiffened heart that can...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters